Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_assertion type Assertion NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_head.
- NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_assertion description "[Routine KRAS/BRAF screening of pathological specimens is required to promote the appropriate clinical use of anti-EGFR mAb and to determine malignant phenotypes in CRC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_provenance.
- NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_assertion evidence source_evidence_literature NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_provenance.
- NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_assertion SIO_000772 22043994 NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_provenance.
- NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_assertion wasDerivedFrom befree-2016 NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_provenance.
- NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_assertion wasGeneratedBy ECO_0000203 NP935299.RASYCQvbbQNzyroGcWCPFzczEjZGXS_8nWVxk-3zWq0fE130_provenance.